Kowa Pharmaceuticals America Announces FDA Acceptance of New Drug Application for K-911, an Investigational IOP-Lowering Eye Drop for Patients with Open-Angle Glaucoma or Ocular Hypertension

NDA FilingK-911Positive

AI Analysis

Summary

Kowa Pharmaceuticals America announced FDA acceptance of a New Drug Application for K-911, a once-daily nitric oxide-donating bimatoprost eye drop for open-angle glaucoma or ocular hypertension, supported by two pivotal Phase 3 trials with a PDUFA target action date of April 30, 2027.

Clinical Trial Data

Phase

Phase 3

Outcome Details

FDA accepted NDA for K-911; PDUFA target action date assigned

Importance:7/10

Sentiment:

0.70

FDA_AcceptanceNDAOphthalmologyGlaucomaPhase_3PDUFA

Related Companies

$AAGH $CBDY

Read the original article

Published by PR Newswire Biotech on August 27, 2026 3:03 PM

Read Original